Use of hospice at end of life is significantly influenced by physician characteristics
the ONA take:
The strongest known predictor of whether a patient will enroll in hospice care is the individual physician the patient sees, according to new research from Brigham and Women’s Hospital.
This factor outweighs other known factors, including geographic location, patient age, race, and comorbidities.
After controlling for other factors that predict hospice enrollment, the researchers found that patients were 27% more likely to enroll in hospice if they saw a physician in the top 10% of hospice use, compared with those who saw a physician in the bottom 10%. In addition, they found that a large number of cancer patients were seen by a relatively small group of physicians.
Study results also showed that regional factors, greater comorbidity, and physician specialty were significantly associated with the likelihood of hospice enrollment.
A new effect seen in this study was physicians associated with for profit hospitals were less likely to have patients enroll in hospice, compared with physicians with non-profit hospitals.
The strongest known predictor of whether a patient will enroll in hospice care is the individual physician the patient sees.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|